Fannie Mae, Freddie Mac shares tumble after conservatorship comments
Sheena Jonathan, co-founder and director of Natera, Inc. (NASDAQ:NTRA), a $20.55 billion market cap company with a "GREAT" financial health score according to InvestingPro, recently sold shares of the company’s common stock, according to a filing with the Securities and Exchange Commission. On April 28, Jonathan sold 439 shares at an average price of $152.18 per share, totaling approximately $66,808. Following this transaction, Jonathan holds 254,914 shares directly. Additionally, she maintains indirect ownership of 40,282 shares each through the Caraluna 1 Trust and Caraluna 2 Trust, although she disclaims beneficial ownership of these securities. The sale comes as Natera demonstrates strong operational performance, with 56.75% revenue growth and a healthy current ratio of 4.0. InvestingPro analysis reveals 8 additional key insights about Natera’s financial position and growth prospects, available to subscribers.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with revenue reaching $476 million, a 53% increase year-over-year, and a narrower-than-expected loss per share of -$0.41. The company also launched the Signatera Genome assay in the U.S., designed for ultra-sensitive detection of circulating tumor DNA in cancer management. Additionally, Natera initiated the HEROES clinical trial in France to explore therapy de-escalation in metastatic HER2+ breast cancer patients using their Signatera test. Analyst firms TD Cowen and Canaccord Genuity both maintained a Buy rating on Natera, with Canaccord Genuity raising its price target from $180 to $195 following the company’s strong fourth-quarter performance. These developments are part of Natera’s continued efforts to expand its product offerings and improve its financial performance, as reflected in the company’s positive cash flow and improved gross margins of 63%. The company also set its 2025 revenue guidance between $1.87 billion and $1.95 billion, indicating a 24% growth at the midpoint.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.